In the bustling streets of Delhi, a new kind of advertisement is quietly catching attention. Prakhar Khanduja, MD of IMM Investment Corp., shared a photo on X (formerly Twitter) of a Lilly banner ad in a mall, commenting, “The Mounjaro epidemic is about to start in the country. I see these US-style D2C advertisements of drugs everywhere in Delhi now.” While the banner itself promoted Lilly’s broader presence, his reference to Mounjaro highlights the growing buzz around US-style weight-loss and diabetes injectables entering India.
The Mounjaro epidemic is about to start in the country.
— Prakhar Khanduja (@prakharkhanduja) February 22, 2026
I see these US style D2C advertisement of drugs everywhere in Delhi now. pic.twitter.com/yn4c40WE14
Mounjaro, also known as tirzepatide, is an injectable prescription medication approved for type 2 diabetes and weight management. It works by reducing appetite and slowing digestion, helping patients manage both blood sugar and weight. While its popularity in the US has sparked cultural debates over lifestyle drugs, India is now witnessing its first wave of adoption.
From the US to India
Eli Lilly launched Mounjaro in India in early 2025, positioning it ahead of competitors like Novo Nordisk’s Ozempic and Wegovy. According to the report, the launch marked a significant move to tap into India’s growing urban health market, targeting not only diabetes patients but also individuals seeking medical support for weight management.
To expand its reach, Lilly partnered with Cipla for distribution and promotion of Yurpeak®, a brand of tirzepatide. The collaboration aims to make the drug more accessible across India, reaching beyond metropolitan centers into smaller towns and cities.
Lifestyle Drugs Meet Indian Aspirations
While Mounjaro’s clinical applications are clear, its entry into India has cultural implications. US-style direct-to-consumer marketing of prescription drugs is rare in India, making these campaigns particularly visible and attention-grabbing. Urban Indians, already attuned to global wellness trends, are beginning to perceive these medications as part of a lifestyle choice, blurring the line between medical treatment and aspirational health.
Social media chatter reflects this intrigue and cautious curiosity. Influencers, fitness enthusiasts, and early adopters are discussing the benefits of Mounjaro, Ozempic, and Wegovy, raising questions about their role beyond clinical use. This mirrors trends in the US, where lifestyle drugs have sparked debates on ethics, accessibility, and medicalization.
The Role of Awareness Campaigns
India is also seeing initiatives that aim to shift the obesity discourse from stigma to medical understanding. Eli Lilly India launched an obesity awareness campaign featuring Boman Irani and Kayoze Irani, blending personal stories with scientific perspectives. The campaign emphasizes that obesity is a health condition that requires professional guidance, not just lifestyle judgment, complementing the introduction of drugs like Mounjaro into the market.
Expert Caution
Despite the buzz, medical experts urge caution. “A comprehensive metabolic evaluation is mandatory before starting therapy,” cautions Dr. Mukesh Budhwani, a senior physician, noting that inappropriate use can lead to persistent nausea and dehydration. He adds that GLP‑1 therapies “must remain under professional medical scrutiny.” (Times of India)
“Wegovy … is not a magic bullet,” says Dr. Ankit Potdar, Consultant Bariatric and Robotic Surgeon, emphasizing that it must be paired with lifestyle changes and careful monitoring. “This is a prescription‑only medicine that should be used only under strict medical supervision,” adds Dr. Sonali Kagne, Consultant Endocrinologist. (Financial Express)
Obesity discourse in India is slowly evolving. Traditionally stigmatized, obesity is now increasingly recognized as a medical condition requiring proper intervention, with awareness campaigns helping balance public curiosity with safe practices.
Market Implications
The rapid entry of US-style lifestyle drugs is not just a health story—it’s a business narrative. Sales figures for Mounjaro in India indicate strong early adoption in urban centers, signaling a lucrative market for pharma companies. Analysts predict that competition from Ozempic, Wegovy, and potential generics will intensify the trend, encouraging broader awareness campaigns and distribution strategies.
Looking Ahead
India’s encounter with Mounjaro and similar injectables reflects a broader cultural and medical shift. Urban consumers are becoming more open to medicalized approaches for weight management, while pharma companies explore new marketing avenues. Campaigns featuring Boman Irani and other personalities underscore a shift in public perception, framing obesity as a medical issue requiring professional guidance. The balance between aspirational use and safe, informed medical practice will define the trajectory of these drugs in India.
As the “Mounjaro Effect” spreads quietly through cities, it serves as a lens into how global health trends intersect with Indian aspirations, commerce, and medical ethics.
Also Read: How Three Indian Women Built an AI Platform Helping Hospitals Diagnose Patients Faster
